Gosselies, Belgium, 16 December 2014 - BONE THERAPEUTICS, the regenerative therapy company addressing unmet medical needs in the field of bone fracture repair and fracture prevention, announces today that its Safety Monitoring Committee (SMC) unanimously recommends the continuation of the Phase I/IIa trial with the allogeneic osteoblastic cell therapy product ALLOB following the treatment of four patients. The study will now proceed as planned and continue with the enrolment of patients.

プレスリリースはこちら